Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Targeted agents have significantly improved outcomes for patients with chronic lymphocytic leukemia, particularly high-risk subgroups for whom chemoimmunotherapy previously offered limited efficacy. Two classes of agent in particular, the Bruton tyrosine kinase inhibitors (e.g., ibrutinib) and the B...

Descripción completa

Detalles Bibliográficos
Autores principales: Lew, Thomas E., Anderson, Mary Ann, Seymour, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992498/
https://www.ncbi.nlm.nih.gov/pubmed/35582452
http://dx.doi.org/10.20517/cdr.2019.108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992498/
https://www.ncbi.nlm.nih.gov/pubmed/35582452
http://dx.doi.org/10.20517/cdr.2019.108

Ejemplares similares